A clinical-stage biopharmaceutical company identifying and developing therapeutics for the treatment of fungal and bacterial infections.
MATINAS BIOPHARMA has raised $3.3M in total funding. The most recent round was Post-IPO Equity. The last funding was announced in February 2025.
MATINAS BIOPHARMA's investors include SternAegis.
MATINAS BIOPHARMA is headquartered in Tarpon Springs, United States.
A clinical-stage biopharmaceutical company identifying and developing therapeutics for the treatment of fungal and bacterial infections.
MATINAS BIOPHARMA is at the Post-IPO Equity stage.
Free to use in articles, research, and reference works. Stable URL — will not change. Data on this page last updated .
"MATINAS BIOPHARMA — Funding & Investors." VCBacked, February 13, 2025, https://www.vcbacked.co/company/matinas-biopharma. Accessed August 14, 2026.
VCBacked. (2025). MATINAS BIOPHARMA — Funding & Investors. Retrieved August 14, 2026, from https://www.vcbacked.co/company/matinas-biopharma
{{cite web |title=MATINAS BIOPHARMA — Funding & Investors |url=https://www.vcbacked.co/company/matinas-biopharma |website=VCBacked |access-date=August 14, 2026}}Profile data sourced and verified per the VCbacked methodology · Last funding round dated